Trial Profile
Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Aprocitentan (Primary)
- Indications Resistant hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PRECISION
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 20 Mar 2024 According to an Idorsia Pharmaceuticals Media Release, announced today that the US Food and Drug Administration (FDA) has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. An investor conference call and webcast will be held on Wed , 20 Mar 2024 15:00hrs CET, to discuss the TRYVIO FDA approval
- 10 Jan 2024 According to an Idorsia Pharmaceuticals Media Release, company expected to achieve FDA decision for the NDA and EMA decision for the MAA for aprocitentan in resistant hypertension in 2024. Other regulatory filings is under preparation.
- 13 Nov 2023 Results assessing percentages of patients achieving BP goals with APRO or placebo (PBO) after 4 weeks of treatment, presented at the American Heart Association Scientific Sessions 2023.